CBLI - Cleveland BioLabs, Inc.
| Previous Close | 1.3700 |
| Open | 1.4730 |
| Bid | 1.00 x 800 |
| Ask | 1.56 x 1100 |
| Day's Range | 1.3900 - 1.4800 |
| 52 Week Range | 1.0000 - 3.9600 |
| Volume | 2,478 |
| Avg. Volume | 8,532 |
| Market Cap | 16.721M |
| Beta (3Y Monthly) | 1.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.38 |
| Earnings Date | May 18, 2017 - May 19, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.00 |
- American City Business Journals•last month
Genome Protection received $10.5M investment from fund controlled by Roman Abramovich
The startup company will seek to develop and commercialize drugs that are capable of prolonging human health and lifespan.
- Simply Wall St.•last month
What does Cleveland BioLabs Inc’s (NASDAQ:CBLI) Balance Sheet Tell Us About Its Future?
Zero-debt allows substantial financial flexibility, especially for small-cap companies like Cleveland BioLabs Inc (NASDAQ:CBLI), as the company does not have to adhere to strict debt covenants. However, it also faces Read More...
- GlobeNewswire•2 months ago
Market Trends Toward New Normal in support, Innovative Solutions and Support, Cleveland BioLabs, Ideal Power, Comstock Holding Companies, and GWG — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- ACCESSWIRE•2 months ago
Cleveland Biolabs Reports Third Quarter 2018 Financial Results and Development Progress
BUFFALO, NY / ACCESSWIRE / November 14, 2018 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the third quarter ended September 30, 2018. Cleveland ...
- Simply Wall St.•4 months ago
The Cleveland BioLabs Inc (NASDAQ:CBLI) Ownership Structure Could Be Important
Every investor in Cleveland BioLabs Inc (NASDAQ:CBLI) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see insiders owning shares Read More...
- ACCESSWIRE•5 months ago
Cleveland Biolabs Reports Second Quarter 2018 Financial Results And Development Progress
BUFFALO, NY / ACCESSWIRE / August 14, 2018 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the second quarter ended June 30, 2018. Cleveland BioLabs ...
- ACCESSWIRE•5 months ago
Cleveland Biolabs Announces Formation and Financing of an Anti-Aging Joint Venture
BUFFALO, NY / ACCESSWIRE / August 14, 2018 / Cleveland BioLabs, Inc. (CBLI) today reported formation of a 50-50 joint venture, named Genome Protection, Inc. (GPI), between the company and Everon BioSciences, Inc. (Everon), a leader in understanding and targeting cellular mechanisms of aging and age-related diseases. GPI's goal is to develop and commercialize drugs for anti-aging applications capable of prolonging human health and life-span. CBLI and Everon contributed relevant IP, technologies and expertise to enable GPI to effectively execute an ambitious research and development program aimed at clinical testing of entolimod and development of new products for anti-aging and other indications associated with genome damage.
- ACCESSWIRE•5 months ago
Cleveland BioLabs Announces Delay in Analysis of Biocomparability Data Required for Regulatory Submission
BUFFALO, NY / ACCESSWIRE / August 6, 2018 / Cleveland BioLabs, Inc. (CBLI) today reported that the company has received vendor notification of delays in analytical analyses of a formulation biocomparability study required for the Company's regulatory submissions. Because the review by the United States Food and Drug Administration (FDA) of the company's pre-Emergency Use Authorization application does not take place on strict timelines, entolimod's review status with the FDA is unaffected.
- ACCESSWIRE•7 months ago
Wired News – Alnylam Pharma Presented New Encouraging Results from Phase-1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type-1
LONDON, UK / ACCESSWIRE / June 12, 2018 / If you want access to our free research report on Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ALNY as the Company’s latest news hit the wire. On June 08, 2018, the Company presented updated positive results from its Phase-1/2 study assessing lumasiran for the treatment of Primary Hyperoxaluria Type-1 (PH1) at the OxalEurope, European Hyperoxaluria Consortium in Naples, Italy. Active-Investors.com is currently working on the research report for Cleveland BioLabs, Inc. (NASDAQ: CBLI), which also belongs to the Healthcare sector as the Company Alnylam Pharma.
- Simply Wall St.•8 months ago
Should You Be Concerned About Cleveland BioLabs Inc’s (NASDAQ:CBLI) Investors?
In this analysis, my focus will be on developing a perspective on Cleveland BioLabs Inc’s (NASDAQ:CBLI) latest ownership structure, a less discussed, but important factor. Ownership structure has been foundRead More...
- ACCESSWIRE•8 months ago
Cleveland Biolabs Reports First Quarter 2018 Financial Results and Development Progress
BUFFALO, NY / ACCESSWIRE / May 15, 2018 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the first quarter ended March 31, 2018. Cleveland BioLabs ...
- Simply Wall St.•9 months ago
Is Cleveland BioLabs Inc’s (NASDAQ:CBLI) CEO Being Overpaid?
Yakov Kogan took the helm as Cleveland BioLabs Inc’s (NASDAQ:CBLI) CEO and grew market cap to US$33.22M recently. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...
- ACCESSWIRE•10 months ago
Cleveland Biolabs Announces Progress on European Marketing Authorization Application
BUFFALO, NY / ACCESSWIRE / March 28, 2018 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported that the company has received Day 120 review questions from the European Medicines Agency (EMA) regarding ...
- ACCESSWIRE•11 months ago
Cleveland Biolabs Reports 2017 Financial Results and Development Progress
BUFFALO, NY / ACCESSWIRE / March 6, 2018 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the fourth quarter and year ended December 31, 2017. Cleveland ...
- Simply Wall St.•11 months ago
Should You Be Concerned About Cleveland BioLabs Inc’s (NASDAQ:CBLI) Investors?
Today, I will be analyzing Cleveland BioLabs Inc’s (NASDAQ:CBLI) recent ownership structure, an important but not-so-popular subject among individual investors. When it comes to ownership structure of a company, theRead More...
- Simply Wall St.•11 months ago
Have Investors Already Priced In Healthcare Growth For Cleveland BioLabs Inc (NASDAQ:CBLI)?
Cleveland BioLabs Inc (NASDAQ:CBLI), a US$39.37M small-cap, is a healthcare company operating in an industry, which has experienced tailwinds from issues such as higher demand driven by an aging populationRead More...
